Evidence map›Paper›PMID 40620045›Full record

ArticleLab on a chip2025

Lossless Altered Histone Modification Analysis System (LAHMAS).

Zachary J Kauffman, Kevin Koesser, Kyle T Helzer, Marina N Sharifi, Erika Heninger, Chao Li, Duane S Juang, David F Jarrard, Shuang G Zhao, Michael C Haffner and 3 more

Abstract read
In one paragraph

Article in Lab on a chip, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zachary J KauffmanDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA. jsperger@medicine.wisc.edu.ORCID 0000-0002-4659-2043
Kevin KoesserDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.
Kyle T HelzerDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.
Marina N SharifiDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA. jsperger@medicine.wisc.edu.
Erika HeningerCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
Chao LiCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
Duane S JuangDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.
David F JarrardDepartment of Urology, University of Wisconsin-Madison, Madison, WI, USA.
Shuang G ZhaoDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.
Michael C HaffnerDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
David J BeebeDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.
Joshua M LangDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA. jsperger@medicine.wisc.edu.
Jamie M SpergerDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA. jsperger@medicine.wisc.edu.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
University of Wisconsin Prostate SPOREP50CA269011 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DAVID F. JARRARD, DOUGLAS G. MCNEEL · 2023 to 2026
$10.6M
The Molecular Drivers and Therapeutic Susceptibilities in Lineage State Transitions of Metastatic Prostate CancerP01CA298991 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Marina Nasrin Sharifi · 2025 to 2026
$7.6M
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase MicrofluidicsR01CA247479 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEEBE, DAVID J, LANG, JOSHUA MICHAEL · 2020 to 2024
$3.1M
The next generation of liquid biopsies: Predictive and pharmacologic biomarkersR50CA293840 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jamie M Sperger · 2024 to 2026
$312k
NCI NIH HHS P01 CA298991NCI NIH HHS P30 CA014520NCI NIH HHS P50 CA269011NCI NIH HHS R01 CA247479NCI NIH HHS R50 CA293840
6 · The paper itself

Abstract

Miniaturized biological assays using microfluidics have the potential to enhance assay sensitivity, reduce reagent consumption, and increase throughput. However, challenges to miniaturization include increased platform complexity and increased surface to volume ratios leading to risk of evaporation and analyte loss through surface binding. Exclusive Liquid Repellency (ELR) enables open microfluidic systems that minimize these challenges through an oil phase that protects small aqueous volumes from temperature fluctuation and evaporation while eliminating surface fouling that leads to sample loss. Here we report a novel microfluidic platform leveraging ELR and Exclusion-based Sample Preparation (ESP) for the miniaturization of CUT&Tag, a complex multistep biological assay. The resultant Lossless Altered Histone Modification Analysis System (LAHMAS) employs a PDMS-silane treated glass surface immersed in silicone oil to facilitate lossless liquid handling and prevent sample evaporation. The device design, compatible with standard laboratory equipment, allows effective processing of cell inputs as low as 100 cells with higher specificity than macroscale CUT&Tag facilitating accurate chromatin profiling of low input and rare cell samples.

Indexed as

HistonesLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesDimethylpolysiloxanesEquipment DesignHumansDimethylpolysiloxanesHistones

Identifiers

PMID40620045
PMCPMC12856978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.